How do you decide between ceftolozane/tazobactam and ceftazidime/avibactam for empiric treatment of an infection due to difficult-to-treat Pseudomonas aeruginosa while awaiting additional susceptibilities?  

Either is generally acceptable. The choice of empiric therapy in this circumstance may be dependent on additional information, if available. As an example, a patient with cystic fibrosis may have recent microbiological data that could guide the decision. Such information, however, is not often avail...

Our institution prefers ceftolozone tazobactam for PSA rather than caz-avi. This is due to data shown above regarding higher rates of clinical success- since both are available to us, we prefer to avoid unnecessary use of caz-avi except for CRE. the only time we use caz avi for PSA is if the patient...